Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis.

Source:http://linkedlifedata.com/resource/pubmed/id/15184610

Neurology 2004 Jun 8 62 11 2031-7

Download in:

View as

General Info

PMID
15184610